Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors

Jirovec, Elise; C.A. Quixabeira, Dafne; H.A. Clubb, James; A. Pakola, Santeri; V. Kudling, Tatiana; Arias, Victor; Haybout, Lyna; Jalkanen, Katriina; Alanko, Tuomo; Monberg, Tine; Khammari, Amir; Dréno, Brigitte; Marie Svane, Inge; S. Block, Matthew; A. Adamo, Daniel; Mäenpää, Johanna; Kistler, Claudia; Sorsa, Suvi; Hemminki, Otto; Kanerva, Anna; M. Santos, João; Cervera-Carrascón, Víctor; Hemminki, Akseli

doi:10.1186/s13046-024-03219-0

Public

Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors

Published in Journal of Experimental & Clinical Cancer Research • Nov 6, 2024

Authors:

Elise Jirovec

Dafne C.A. Quixabeira

James H.A. Clubb

Abstract

BACKGROUND: A limitation of approved oncolytic viruses is their requirement for intratumoral (i.t.) injection. TILT-123 (igrelimogene litadenorepvec, Ad5/3-E2F-D24-hTNFα-IRES-hIL-2) is a chimeric oncolytic adenovirus suitable for intravenous (i.v.) delivery due to its capsid modification and dual se...

Subject

Oncolytic virus

Oncolytic adenovirus

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!